MedTrace Logo

PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer

NCT06320223 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2024-03-20

No results posted yet for this study

Summary

Background:

PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.

Need:

Improved prognostication across various stages of prostate cancer is needed for management guidance and study design.

Aim:

1. To assess the prognostic value of PSMA PET
2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages

Inclusion:

* Adult patients with
* biopsy/histo proven prostate cancer who
* underwent PSMA PET (any type)
* for staging or re-staging at any stage and who
* have at least 3-year overall survival follow-up data available will be included consecutively.

Exclusion:

* Patients with neuroendocrine prostate cancer
* Patients with metastasized or disseminated malignancy other than prostate cancer

Conditions

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Wolfgang P Fendler, M.D. · University Hospital, Essen

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-05
Primary Completion
2034-03-05
Completion
2035-03-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06320223 on ClinicalTrials.gov